Abstract 195P
Background
The effectiveness of durvalumab in the treatment of stage III unresectable non-small cell lung cancer (NSCLC) in real-world clinical practice remains insufficiently studied.
Methods
Retrospective cohort study of patients with stage III unresectable NSCLC treated with durvalumab after chemoradiotherapy at Hospital Italiano de Buenos Aires from 2020 to 2023.
Results
A total of 42 patients were treated, with a median age of 67 years; 62% were male, and 95% had a PS of 0–1. Smoking history was observed in 86%, 81% had adenocarcinoma, and 48% were PD-L1 positive. With a median follow-up of 23 months, 66% remained progression-free (PFS) at 12 months, and 59% at 18 months. Median PFS was not reached. PD-L1 expression below 1% was associated with higher PFS risk (HR 3.2; p=0.04), as was PS ≥2 (HR 6.4; p=0.001). Clinically significant adverse events were observed in 33%, with pneumonitis and neurological symptoms being the main causes of treatment discontinuation (10%). At 12 and 18 months, 83% and 76% of patients were alive, respectively. Overall survival was also higher in PDL1-positive patients.
Conclusions
This real-world evidence study supports the effectiveness of durvalumab in a population underrepresented in pivotal trials, highlighting its applicability in routine clinical practice. The results align with the PACIFIC trial but underscore challenges related to toxicities and the heterogeneity of real-world cohorts.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.